Veracyte (VCYT) Current Deferred Revenue (2012 - 2026)

Veracyte has reported Current Deferred Revenue for 13 years, with the latest figure at $597000.0 in Q2 2026.

• Current Deferred Revenue for Q2 2026 came in at $597000.0, down 58.83% year-over-year; the trailing twelve-month figure through Jun 2026 was $597000.0 (down 58.83% YoY), and the FY2025 annual result was $1.2 million, down 30.66% from the prior year.
• Current Deferred Revenue retreated to $597000.0 in Q2 2026, from $749000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $4.9 million in Q1 2022 and troughed at $417000.0 in Q3 2025.
• A 5-year average of $2.2 million and a median of $2.1 million in 2023 frame the typical range for Current Deferred Revenue.
• The widest annual swing landed in 2022, when Current Deferred Revenue jumped 974.45%; it then slumped 79.49% in 2025.
• A 5-year view of Current Deferred Revenue shows it stood at $2.6 million in 2022, then declined by 23.15% to $2.0 million in 2023, then retreated by 16.68% to $1.7 million in 2024, then slumped by 30.66% to $1.2 million in 2025, then slumped by 48.53% to $597000.0 in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $597000.0 in Q2 2026, $749000.0 in Q1 2026, and $1.2 million in Q4 2025.